← All trials
NCT07254806
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2025
- Primary completion
- Nov 24, 2027
- Completion date
- Nov 24, 2028
- First posted
- Nov 28, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- DiscGenics, Inc.Lead sponsor
- DiscGenics, Inc.Official
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.